Corporate News

Concepta plc (AIM:CPT), the pioneering UK healthcare company and developer of a proprietary platform and suite of products targeted at the personalised mobile health market with a primary focus on women's fertility and specifically unexplained infertility, announces that Admission of its Enlarged Share Capital to trading on AIM has now commenced under the symbol "CPT". SPARK Advisory Partners is acting as Nominated Adviser and Financial Adviser to the Company with Beaufort Capital as Broker.

• Innovative player in the Mobile Health and Connected Health Sector
• Developed pioneering product 'MyLotus' for home self-testing that helps women with unexplained infertility to conceive
• MyLotus - only known consumer product to allow both quantitative and qualitative measurement of a woman's personal hCG and LH hormone levels in urine samples to help increase conception rates
• Defined route to market:
  • Regulatory approvals in place for launch in China - first order from distributor with payment in advance expected after AIM admission
  • CE-Marking for UK and Europe to follow in 2017
• Significant market opportunity - Chinese and EU infertility market worth c.£600m per annum
• Management has proven track record in the women's health diagnostics industry
• New Product Development growth opportunities - proprietary platform lends itself to wider family home-health monitoring to improve individual health parameters including chronic stress, inflammation, urinary tract and healthy pregnancy progression et al.
  

Concepta's AIM Admission follows a reverse takeover from Frontier Resources International plc ("Frontier"), the details of which can be found in the announcement made by Frontier on 25 July 2016 'Result Of General Meetings And Open Offer'.

Erik Henau, Chief Executive Officer of Concepta plc said: "We are delighted to be joining AIM at this transformational juncture of our development and believe our listing will significantly enhance our profile and visibility with future customers and partners, as we look to launch our pioneering 'My Lotus' product, targeted at helping women with unexplained infertility to conceive, across key international growth markets.

"Unexplained infertility refers to women who have been unable to conceive after six months of trying for a baby. The issue is universal and largely unaffected by demographics, and accounts for 0.36% of the total population in any given market.  Many women within this group often have to wait months or even years before they are eligible for medical intervention which can lead to a long and worrying wait for women and families, not knowing whether or not anything is wrong.  As such, the market opportunity for a 'best in class' product specifically aiming to help women with unexplained infertility to conceive is huge, representing a highly motivated yet neglected group. 

"We are expecting a highly active start to our life on AIM, with the roll out of My Lotus in China set to commence in Q3 2016 and thereafter in the UK and Europe in 2017.  In addition, our proprietary platform lends itself to wider family home-health monitoring, and we believe there are exciting growth opportunities for Concepta in the future within the growing global connected healthcare sector set to be worth $61bn by 2020 (PwC).

 "Finally, the board joins me in welcoming our new and existing shareholders to our register and we now look forward to implementing our defined growth strategy focused on delivering commercial success and becoming the global market leaders for over-the counter products for women with fertility issues."

Enquiries:

The Company

Adam Reynolds, Chairman

Tel: +44 (0) 7785 908158

SPARK Advisory Partners Limited (Nomad)

Neil Baldwin/Mark Brady

Tel: +44 (0)20 368 3550

Beaufort Securities Limited (Broker)

Jon Belliss

Tel: +44 (0)20 7382 8300

Yellow Jersey PR Limited (Financial PR)

Felicity Winkles/ Joe Burgess/ Josh Cole

Tel: +44 (0) 7748 843 871

About Concepta Plc:

Concepta plc is a pioneering UK healthcare company that has developed a proprietary platform and products targeted at the personalised mobile health market with a primary focus on women's fertility and specifically unexplained infertility*.

Founded in 2013, Concepta has developed a revolutionary flagship product 'MyLotus' for home self-testing that helps women with unexplained infertility to conceive.  

MyLotus is the only consumer product which allows both quantitative and qualitative measurements of measurement of a woman's personal hCG and LH hormone levels in an easy to use home test to facilitate higher conception rates and early diagnosis of any fertility problems.  Competitor products currently only allow qualitative measurement and are based on the 'average woman'.  

Concepta has a defined route to market for its new 'My Lotus' product with Regulatory approvals for launch in China in place for 2016 and CE-Marking for UK and Europe to follow in 2017 where the revenue potential of the Chinese and EU infertility market is worth c.£600m per annum for the company.

*Unexplained infertility refers to women that have been unable to conceive after 6 months of trying. This highly motivated target group of consumers won't typically be offered medical intervention until 12 months of unsuccessfully trying, with IVF not offered until two years. Research indicates couples start to take positive action ahead of this time and there is little medical support to help them do so.